@article{ProetelPletschLausekeretal.2014,
  author    = {Proetel, Ulrike and Pletsch, Nadine and Lauseker, Michael and M{\"u}ller, Martin C. and Hanfstein, Benjamin and Krause, Stefan W. and Kalmanti, Lida and Schreiber, Annette and Heim, Dominik and Baerlocher, Gabriela M. and Hofmann, Wolf-Karsten and Lange, Elisabeth and Einsele, Hermann and Wernli, Martin and Kremers, Stephan and Schlag, Rudolf and M{\"u}ller, Lothar and H{\"a}nel, Mathias and Link, Hartmut and Hertenstein, Bernd and Pfirrmann, Markus and Hochhaus, Andreas and Hasford, Joerg and Hehlmann, R{\"u}diger and Saußele, Susanne},
  title     = {Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV},
  series = {Annals of Hematology},
  volume    = {93},
  journal   = {Annals of Hematology},
  number    = {7},
  issn      = {0939-5555},
  doi       = {10.1007/s00277-014-2041-0},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-121574},
  pages     = {1167-76},
  year      = {2014},
  abstract  = {The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid leukemia in chronic phase. Patients randomized to imatinib 400 mg/day (IM400) or imatinib 800 mg/day (IM800) and stratified according to age (≥65 years vs. <65 years) were compared regarding dose, response, adverse events, rates of progression, and survival. The full 800 mg dose was given after a 6-week run-in period with imatinib 400 mg/day. The dose could then be reduced according to tolerability. A total of 828 patients were randomized to IM400 or IM800. Seven hundred eighty-four patients were evaluable (IM400, 382; IM800, 402). One hundred ten patients (29 \%) on IM400 and 83 (21 \%) on IM800 were ≥65 years. The median dose per day was lower for patients ≥65 years on IM800, with the highest median dose in the first year (466 mg/day for patients ≥65 years vs. 630 mg/day for patients <65 years). Older patients on IM800 achieved major molecular remission and deep molecular remission as fast as younger patients, in contrast to standard dose imatinib with which older patients achieved remissions much later than younger patients. Grades 3 and 4 adverse events were similar in both age groups. Five-year relative survival for older patients was comparable to that of younger patients. We suggest that the optimal dose for older patients is higher than 400 mg/day. ClinicalTrials.gov identifier: NCT00055874},
  language  = {en}
}
@article{RostMuellerKelleretal.2014,
  author    = {Rost, Simone and M{\"u}ller, Elisabeth and Keller, Alexander and Fregin, Andreas and M{\"u}ller, Clemens R.},
  title     = {Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling},
  doi       = {10.1186/1471-2156-15-17},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-110095},
  year      = {2014},
  abstract  = {Background VKORC1 has been identified some years ago as the gene encoding vitamin K epoxide reductase (VKOR) - the target protein for coumarin derivates like warfarin or phenprocoumon. Resistance against warfarin and other coumarin-type anticoagulants has been frequently reported over the last 50 years in rodents due to problems in pest control as well as in thrombophilic patients showing variable response to anticoagulant treatment. Many different mutations have already been detected in the VKORC1 gene leading to warfarin resistance in rats, mice and in humans. Since the conventional in vitro dithiothreitol (DTT)-driven VKOR enzymatic assay often did not reflect the in vivo status concerning warfarin resistance, we recently developed a cell culture-based method for coexpression of VKORC1 with coagulation factor IX and subsequent measurement of secreted FIX in order to test warfarin inhibition in wild-type and mutated VKORC1. Results In the present study, we coexpressed wild-type factor IX with 12 different VKORC1 variants which were previously detected in warfarin resistant rats and mice. The results show that amino acid substitutions in VKORC1 maintain VKOR activity and are associated with warfarin resistance. When we projected in silico the amino acid substitutions onto the published three-dimensional model of the bacterial VKOR enzyme, the predicted effects matched well the catalytic mechanism proposed for the bacterial enzyme. Conclusions The established cell-based system for coexpression of VKORC1 and factor IX uses FIX activity as an indicator of carboxylation efficiency. This system reflects the warfarin resistance status of VKORC1 mutations from anticoagulant resistant rodents more closely than the traditional DTT-driven enzyme assay. All mutations studied were also predicted to be involved in the reaction mechanism.},
  language  = {en}
}
@article{SchuemannGrossBaueretal.2021,
  author    = {Sch{\"u}mann, Franziska Lea and Groß, Elisabeth and Bauer, Marcus and Rohde, Christian and Sandmann, Sarah and Terziev, Denis and M{\"u}ller, Lutz P. and Posern, Guido and Wienke, Andreas and Fend, Falko and Hansmann, Martin-Leo and Klapper, Wolfram and Rosenwald, Andreas and Stein, Harald and Dugas, Martin and M{\"u}ller-Tidow, Carsten and Wickenhauser, Claudia and Binder, Mascha and Weber, Thomas},
  title     = {Divergent effects of EZH1 and EZH2 protein expression on the prognosis of patients with T-cell lymphomas},
  series = {Biomedicines},
  volume    = {9},
  journal   = {Biomedicines},
  number    = {12},
  issn      = {2227-9059},
  doi       = {10.3390/biomedicines9121842},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-252155},
  year      = {2021},
  abstract  = {T-cell lymphomas are highly heterogeneous and their prognosis is poor under the currently available therapies. Enhancers of zeste homologue 1 and 2 (EZH1/2) are histone H3 lysine-27 trimethyltransferases (H3K27me3). Despite the rapid development of new drugs inhibiting EZH2 and/or EZH1, the molecular interplay of these proteins and the impact on disease progression and prognosis of patients with T-cell lymphomas remains insufficiently understood. In this study, EZH1/2 mutation status was evaluated in 33 monomorphic epitheliotropic intestinal T-cell lymphomas by next generation sequencing and EZH1/2 and H3K27me3 protein expression levels were detected by immunohistochemistry in 46 T-cell lymphomas. Correlations with clinicopathologic features were analyzed and survival curves generated. No EZH1 mutations and one (3\%) EZH2 missense mutation were identified. In univariable analysis, high EZH1 expression was associated with an improved overall survival (OS) and progression-free survival (PFS) whereas high EZH2 and H3K27me3 expression were associated with poorer OS and PFS. Multivariable analysis revealed EZH1 (hazard ratio (HR) = 0.183; 95\% confidence interval (CI): 0.044-0.767; p = 0.020;) and EZH2 (HR = 8.245; 95\% CI: 1.898-35.826; p = 0.005) to be independent, divergent prognostic markers for OS. In conclusion, EZH1/2 protein expression had opposing effects on the prognosis of T-cell lymphoma patients.},
  language  = {en}
}
@article{HeisswolfGablerObermaieretal.2007,
  author    = {Heisswolf, Annette and Gabler, Dirk and Obermaier, Elisabeth and M{\"u}ller, Caroline},
  title     = {Olfactory versus contact cues in host plant recognition of a monophagous chrysomelid beetle},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-49475},
  year      = {2007},
  abstract  = {The importance of olfactory versus contact cues for host plant recognition was investigated in the tortoise beetle Cassida canaliculata Laich. (Coleoptera: Chrysomelidae), which is strictly monophagous on meadow sage. The reaction of adult beetles to olfactory and contact host cues was tested using three bioassays (locomotion compensator, six-chamber-olfactometer, stem arena') to account for different behavioral contexts. Bioassay-guided fractionation of plant extracts was elaborated to characterize the nature of contact stimuli. The beetles were only slightly attracted to odors from small amounts of leaf material. However, when contact cues were provided additionally, the beetles showed strong preferences for samples of their host plant over controls. Bioassay-guided fractionation led to isolation of at least two non-polar contact stimuli acting in concert that are sufficient for host plant identification in C. canaliculata.},
  subject      = {Insekt},
  language  = {en}
}
@phdthesis{Mueller2015,
  author    = {M{\"u}ller, Elisabeth},
  title     = {Pan-Raf-Inhibition als neue therapeutische Strategie im Multiplen Myelom},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-124666},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Das Multiple Myelom (MM) ist eine durch monoklonale Vermehrung terminal differenzierter Antik{\"o}rper-produzierender B-Lymphozyten (Plasmazellen) im Knochenmark charakterisierte maligne Krankheit, die sich v.a. in osteolytischen Knochendestruktionen, h{\"a}matopoetischer und Niereninsuffizienz {\"a}ußert. Verbesserte Therapieans{\"a}tze wie die Hochdosis-Chemotherapie mit Melphalan und anschließender autologer Stammzelltransplantation sowie die Einf{\"u}hrung neuer pharmakologischer Substanzklassen (Proteasom-Inhibitoren, Cereblon-bindende Thalidomidderivate) f{\"u}hrten zu einer Verl{\"a}ngerung der durchschnittlichen {\"U}berlebenszeit, f{\"u}r die meisten der Patienten ist die Erkrankung jedoch derzeit unheilbar. Die Erforschung neuer potenzieller therapeutischer Angriffspunkte auf Grund pathobiologischer Erkenntnisse bleibt daher unabdingbar. Ein Ansatz zur Verbesserung des Verst{\"a}ndnisses der Pathogenese ist die funktionelle, molekulare und genetische Analyse des Signalnetzwerkes im MM. Im Zusammenhang mit diesem Konzept wurde entdeckt, dass wachstums-regulierende Signalwege in MM Zellen aktiviert oder dereguliert sind und zum {\"U}berleben und der Proliferation des Tumors beitragen. So konnte beispielsweise von unserer Arbeitsgruppe bereits gezeigt werden, dass onkogenes Ras essentiell zum {\"U}berleben der MM Zellen beitr{\"a}gt. Da Ras derzeit mangels spezifischer Inhibitoren pharmakologisch nicht angreifbar ist, stellen weitere funktionelle Bestandteile des Signalweges eine potenzielle therapeutische Zielstruktur dar. W{\"a}hrend die Blockade von MEK1/2 in MM Zellen keinen Einfluss auf das {\"U}berleben hatte, konnte durch die Blockade von Raf in ersten Tests unserer Arbeitsgruppe Apoptose hervorgerufen werden. Aus diesem Grund habe ich in der vorliegenden Arbeit zur Evaluation eines neuen Therapieansatzes die Rolle der Raf-abh{\"a}ngigen Signaltransduktion eingehend untersucht. Als Grundlage diente dabei die Hypothese, dass die Raf-Kinasen entscheidende Effektoren der durch onkogenes Ras vermittelten apoptotischen Effekte darstellen. In einem ersten Schritt konnte ich nachweisen, dass alle drei Raf-Isoformen (A-, B- und C-Raf) in humanen MM Zelllinien und in prim{\"a}ren MM Zellen aktiviert sind. Mittels shRNA-vermittelter, Isoform-spezifischer Raf-Knockdown-Experimente konnte ich zeigen, dass nur ein simultaner Knockdown aller Isoformen, d.h. ein Pan-Raf-Knockdown, zu einer De-Phosphorylierung von MEK1/2 und ERK1/2 f{\"u}hrte. Dieser Versuch ließ sich mittels pharmakologischer Raf-Inhibition, bei der ebenfalls nur eine Pan-Raf-Blockade zu einer Herunterregulation von MEK1/2 und ERK1/2 in MM Zellen f{\"u}hrte, best{\"a}tigen. Das MEK/ERK-Modul stellte somit einen hervorragenden Surrogat- und Biomarker f{\"u}r die Pan-Raf-Aktivit{\"a}t dar. Im Gegensatz zur Blockade des MEK/ERK-Moduls f{\"u}hrte eine Hemmung der Pan-Raf-Aktivit{\"a}t mittels shRNA oder pharmakologischer Inhibitoren in allen untersuchten Zelllinien und in der Mehrheit der prim{\"a}ren MM Zellen zu einer starken Induktion von Apoptose. Da das Ansprechen auf eine Pan-Raf-Blockade nicht mit dem Ras-Mutationsstatus korrelierte, k{\"o}nnten die Raf-Kinasen eine von onkogenem Ras unabh{\"a}ngie Qualit{\"a}t als therapeutische Zielstruktur aufweisen. Zur Untersuchung m{\"o}glicher MEK/ERK-unabh{\"a}ngiger Effektormechanismen der Pan-Raf-Inhibition habe ich die mRNA-basierten Genexpressionsprofile von INA-6 Zellen nach pharmakologischer Pan-Raf- oder MEK-Inhibition verglichen. Dabei f{\"u}hrte die Pan-Raf-Inhibition zu einer Regulation von wesentlich mehr Genen, wobei sich auch die Art der regulierten Gene unterschied, darunter Gene mit tumorrelevanten Funktionen wie Regulation von Proliferation, Zellzyklus und Apoptose. F{\"u}r eine dieser Gengruppen, die Gruppe der PI3K-abh{\"a}ngigen, mTOR-assoziierten Gene, konnte ich eine Regulation auch auf der Proteinebene nachweisen: die Phosphorylierungen von mTOR, p70S6K, Rb und AKT und die Expression von CyclinD1 und PDK1 waren nach Pan-Raf-Inhibition, nicht jedoch nach MEK-Blockade herunterreguliert. Dieses Ergebnis deutet auf eine Ko-Regulation der PI3K-abh{\"a}ngigen Signaltransduktion durch die Raf-kinasen hin. Mittels spezifischer PI3K-Inhibitoren ließ sich sowohl bei der Regulation der untersuchten Proteine als auch bei der Induktion von Apoptose eine deutliche Verst{\"a}rkung der Pan-Raf-Inhibition in HMZL und in prim{\"a}ren Zellen erzielen. Zusammengefasst zeigt diese Arbeit, dass die Pan-Raf-Blockade eine neue Therapiem{\"o}glichkeit darstellt, die durch Kombination mit einer PI3K/AKT-Inhibition noch verst{\"a}rkt werden kann.},
  subject      = {Plasmozytom},
  language  = {de}
}
@techreport{MuellerBrandeckBocquetGiegLowingeretal.2015,
  type      = {Working Paper},
  author    = {M{\"u}ller-Brandeck-Bocquet, Gisela and Gieg, Philipp and Lowinger, Timo and Gs{\"a}nger, Matthias and Becker, Michael and Kundu, Amitabh and Valerian, Rodrigues and S, Shaji and Sch{\"o}mbucher-Kusterer, Elisabeth and Biswas, Aparajita},
  title     = {Exploring Emerging India - Eight Essays},
  editor    = {M{\"u}ller-Brandeck-Bocquet, Gisela and Gieg, Philipp and Lowinger, Timo},
  doi       = {10.25972/OPUS-11997},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-119973},
  pages     = {58},
  year      = {2015},
  abstract  = {India's economic rise since the 1990s has been followed by a more prominent global role for the country. Despite economic setbacks in recent years and huge domestic challenges like poverty, caste issues, and gender inequality, India today is almost universally characterised as an "emerging power". At the same time, the country continues to show an enormous diversity. Thus, exploring emerging India can surely not be confined to economic analysis only. Instead, it is vital to take current developments in domestic and international politics, society, culture, religion, and political thinking into consideration as well. Following an interdisciplinary approach, contributions from Political Science, International Relations, Indology, Political Theory, and Economics are fundamental in order to grasp the country's diversity. This collection assembles eight essays which, individually, serve as working papers reflecting the authors' various research focuses, while collectively composing a multifaceted and multidis-ciplinary picture of emerging India. It thereby reflects the approach the University of W{\"u}rz-burg's Centre for Modern India and the Institute for Political Science and Sociology's India Forum are committed to: bringing together different academic disciplines in order to generate nuanced insights into India's manifold diversity.},
  subject      = {Indien / Government},
  language  = {en}
}
@article{SteinmannPaeleckeHabermannGeinitzetal.2012,
  author    = {Steinmann, Diana and Paelecke-Habermann, Yvonne and Geinitz, Hans and Aschoff, Raimund and Bayerl, Anja and B{\"o}lling, Tobias and Bosch, Elisabeth and Bruns, Frank and Eichenseder-Seiss, Ute and Gerstein, Johanna and Gharbi, Nadine and Hagg, Juliane and Hipp, Matthias and Kleff, Irmgard and M{\"u}ller, Axel and Sch{\"a}fer, Christof and Schleicher, Ursula and Sehlen, Susanne and Theodorou, Marilena and Wypior, Hans-Joachim and Zehentmayr, Franz and van Oorschot, Birgitt and Vordermark, Dirk},
  title     = {Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases},
  series = {BMC Cancer},
  volume    = {12},
  journal   = {BMC Cancer},
  number    = {283},
  doi       = {10.1186/1471-2407-12-283},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-135254},
  year      = {2012},
  abstract  = {Background: Recently published results of quality of life (QoL) studies indicated different outcomes of palliative radiotherapy for brain metastases. This prospective multi-center QoL study of patients with brain metastases was designed to investigate which QoL domains improve or worsen after palliative radiotherapy and which might provide prognostic information. Methods: From 01/2007-01/2009, n=151 patients with previously untreated brain metastases were recruited at 14 centers in Germany and Austria. Most patients (82 \%) received whole-brain radiotherapy. QoL was measured with the EORTC-QLQ-C15-PAL and brain module BN20 before the start of radiotherapy and after 3 months. Results: At 3 months, 88/142 (62 \%) survived. Nine patients were not able to be followed up. 62 patients (70.5 \% of 3-month survivors) completed the second set of questionnaires. Three months after the start of radiotherapy QoL deteriorated significantly in the areas of global QoL, physical function, fatigue, nausea, pain, appetite loss, hair loss, drowsiness, motor dysfunction, communication deficit and weakness of legs. Although the use of corticosteroid at 3 months could be reduced compared to pre-treatment (63 \% vs. 37 \%), the score for headaches remained stable. Initial QoL at the start of treatment was better in those alive than in those deceased at 3 months, significantly for physical function, motor dysfunction and the symptom scales fatigue, pain, appetite loss and weakness of legs. In a multivariate model, lower Karnofsky performance score, higher age and higher pain ratings before radiotherapy were prognostic of 3-month survival. Conclusions: Moderate deterioration in several QoL domains was predominantly observed three months after start of palliative radiotherapy for brain metastases. Future studies will need to address the individual subjective benefit or burden from such treatment. Baseline QoL scores before palliative radiotherapy for brain metastases may contain prognostic information.},
  language  = {en}
}
@article{ChatterjeeAndrulisStuehmeretal.2013,
  author    = {Chatterjee, Manik and Andrulis, Mindaugas and St{\"u}hmer, Thorsten and M{\"u}ller, Elisabeth and Hofmann, Claudia and Steinbrunn, Torsten and Heimberger, Tanja and Schraud, Heike and Kressmann, Stefanie and Einsele, Hermann and Bargou, Ralf C.},
  title     = {The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma},
  series = {Haematologica},
  volume    = {98},
  journal   = {Haematologica},
  number    = {7},
  doi       = {10.3324/haematol.2012.066175},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-130574},
  pages     = {1132-1141},
  year      = {2013},
  abstract  = {Despite therapeutic advances multiple myeloma remains largely incurable, and novel therapeutic concepts are needed. The Hsp90-chaperone is a reasonable therapeutic target, because it maintains oncogenic signaling of multiple deregulated pathways. However, in contrast to promising pre-clinical results, only limited clinical efficacy has been achieved through pharmacological Hsp90 inhibition. Because Hsp70 has been described to interact functionally with the Hsp90-complex, we analyzed the suitability of Hsp72 and Hsp73 as potential additional target sites. Expression of Hsp72 and Hsp73 in myeloma cells was analyzed by immunohistochemical staining and western blotting. Short interfering RNA-mediated knockdown or pharmacological inhibition of Hsp72 and Hsp73 was performed to evaluate the role of these proteins in myeloma cell survival and for Hsp90-chaperone function. Furthermore, the role of PI3K-dependent signaling in constitutive and inducible Hsp70 expression was investigated using short interfering RNA-mediated and pharmacological PI3K inhibition. Hsp72 and Hsp73 were frequently overexpressed in multiple myeloma. Knockdown of Hsp72 and/or Hsp73 or treatment with VER-155008 induced apoptosis of myeloma cells. Hsp72/Hsp73 inhibition decreased protein levels of Hsp90-chaperone clients affecting multiple oncogenic signaling pathways, and acted synergistically with the Hsp90 inhibitor NVP-AUY922 in the induction of death of myeloma cells. Inhibition of the PI3K/Akt/GSK3b pathway with short interfering RNA or PI103 decreased expression of the heat shock transcription factor 1 and down-regulated constitutive and inducible Hsp70 expression. Treatment of myeloma cells with a combination of NVP-AUY922 and PI103 resulted in additive to synergistic cytotoxicity. In conclusion, Hsp72 and Hsp73 sustain Hsp90-haperone function and critically contribute to the survival of myeloma cells. Translation of Hsp70 inhibition into the clinic is therefore highly desirable. Treatment with PI3K inhibitors might represent an alternative therapeutic strategy to target Hsp70.},
  language  = {en}
}
@phdthesis{Mueller2006,
  author    = {M{\"u}ller, Katharina Elisabeth},
  title     = {Ergebnisse der transskleralen Einn{\"a}hung von Hinterkammerlinsen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-22626},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2006},
  abstract  = {Die transsklerale Einn{\"a}hung von Hinterkammerlinsen ist heutzutage eine etablierte Operationstechnik zur funktionellen Rehabilitation von Augen mit teilweise besch{\"a}digtem oder g{\"a}nzlich fehlendem Kapselhalteapparat. In der vorgestellten Studie wurden die Akten von 65 Patienten retrospektiv ausgewertet, denen von einem Operateur im Zeitraum von April 1996 bis M{\"a}rz 2004 eine HKL nach der modifizierten Methode von Mittelviefhaus und Wiek transskleral eingen{\"a}ht wurde. 39 (60\%) der Patienten waren m{\"a}nnlich und 26 (40\%) weiblich. Der Altersdurchschnitt betrug 64,9 Jahre (9-90 Jahre). Der Großteil der Augen war voroperiert und hatte einen oder mehrere zus{\"a}tzliche pathologische Befunde. 36 der Patienten waren vor dem Eingriff pseudophak, 21 waren aphak und 8 waren phak. Der Eingriff dauerte bei den 65 Patienten im Mittel 70,4 ± 18,0 Minuten (38-136 Minuten). Die Nachuntersuchungen erfolgten 6 Wochen, 24 Wochen, 52 Wochen und 3 Jahre nach der Operation. Die mitt-lere Nachbeobachtungsdauer betrug 20 Monate (0-3,4 Jahre). Nach 6 Wochen erschie-nen 59 Patienten, nach 24 und 52 Wochen jeweils 44 Patienten und nach 3 Jahren noch 33 Patienten zur Nachuntersuchung. Wie die Ergebnisse zeigten, betrug die Refraktionsabweichung nach einem Jahr im Mit-tel 1,73 dpt. Innerhalb ± 2 dpt befanden sich 61,76\% der Patienten und innerhalb ± 1 dpt 29,41\% der Patienten. Nach 3 Jahren lag die Refraktionsabweichung im Mittel bei 1,82 dpt. 60\% befanden sich innerhalb ± 2 dpt und 36\% innerhalb ± 1 dpt. Die Refraktionsaberration zeigte eine deutlich myope Tendenz, denn bei den jeweiligen Untersuchungen waren 65\%, 74\% und 72\% der Werte myoper als die berechnete Zielrefraktion. Der pr{\"a}operative Durchschnittsvisus betrug 0,27, nach 3 Jahren lag er bei 0,33. Nach 3 Jahren waren bei 52\% der erschienenen Patienten die Visuswerte besser, bei 39\% schlechter und bei 9\% unver{\"a}ndert im Vergleich zu den pr{\"a}operativ ermittelten Werten. Insgesamt fand eine leichte Visusverbesserung statt. Postoperativ unerw{\"u}nschte Befunde stellten 3 zystoide Makula{\"o}deme (2 nach 6 Wo-chen, 1 nach einem Jahr) und 3 Netzhautabl{\"o}sungen (2 nach 6 Wochen, 1 nach 3 Jah-ren) dar. Von den beiden nach 6 Wochen aufgetretenen zystoiden Makula{\"o}demen konnte eines behandelt werden, der andere Patient erschien zu keiner weiteren Untersuchung. Das {\"O}dem, das nach einem Jahr aufgetreten war, resorbierte von selbst. Die beiden nach 6 Wochen aufgetretenen Ablationes wurden mit einer Cerclage wieder zum Anliegen gebracht, der andere Patient mit Ablatio erschien zu keiner der weiteren Untersuchungen. Bei zwei Patienten musste ein weiterer Eingriff erfolgen, jedoch nicht unmittelbar aus Gr{\"u}nden der HKL-Einn{\"a}hung. Postoperativ ereigneten sich keine Linsendislokationen. Die Ergebnisse unserer Arbeit bez{\"u}glich des postoperativen Visusverlaufs, der Refraktionsaberration, des Auftretens von Netzhautpathologien und HKL-Dislokation bewegen sich innerhalb der in der Literatur angegebenen H{\"a}ufigkeiten. Man sollte dabei allerdings ber{\"u}cksichtigen, dass unterschiedliche Studienbedingungen und Patienteng{\"u}ter ebenso wie differierende Untersuchungszeitr{\"a}ume die Grundlage f{\"u}r eine absolute Ver-gleichbarkeit entziehen.},
  language  = {de}
}
@article{MorrisCarusoBuscotetal.2014,
  author    = {Morris, E. Kathryn and Caruso, Tancredi and Buscot, Francois and Fischer, Markus and Hancock, Christine and Maier, Tanja S. and Meiners, Torsten and M{\"u}ller, Caroline and Obermaier, Elisabeth and Prati, Daniel and Socher, Stephanie A. and Sonnemann, Ilja and W{\"a}schke, Nicola and Wubet, Tesfaye and Wurst, Susanne and Rillig, Matthias C.},
  title     = {Choosing and using diversity indices: insights for ecological applications from the German Biodiversity Exploratories},
  series = {Ecology and Evolution},
  volume    = {4},
  journal   = {Ecology and Evolution},
  number    = {18},
  issn      = {2045-7758},
  doi       = {10.1002/ece3.1155},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-115462},
  pages     = {3514-3524},
  year      = {2014},
  abstract  = {Biodiversity, a multidimensional property of natural systems, is difficult to quantify partly because of the multitude of indices proposed for this purpose. Indices aim to describe general properties of communities that allow us to compare different regions, taxa, and trophic levels. Therefore, they are of fundamental importance for environmental monitoring and conservation, although there is no consensus about which indices are more appropriate and informative. We tested several common diversity indices in a range of simple to complex statistical analyses in order to determine whether some were better suited for certain analyses than others. We used data collected around the focal plant Plantago lanceolata on 60 temperate grassland plots embedded in an agricultural landscape to explore relationships between the common diversity indices of species richness (S), Shannon's diversity (H'), Simpson's diversity (D-1), Simpson's dominance (D-2), Simpson's evenness (E), and Berger-Parker dominance (BP). We calculated each of these indices for herbaceous plants, arbuscular mycorrhizal fungi, aboveground arthropods, belowground insect larvae, and P.lanceolata molecular and chemical diversity. Including these trait-based measures of diversity allowed us to test whether or not they behaved similarly to the better studied species diversity. We used path analysis to determine whether compound indices detected more relationships between diversities of different organisms and traits than more basic indices. In the path models, more paths were significant when using H', even though all models except that with E were equally reliable. This demonstrates that while common diversity indices may appear interchangeable in simple analyses, when considering complex interactions, the choice of index can profoundly alter the interpretation of results. Data mining in order to identify the index producing the most significant results should be avoided, but simultaneously considering analyses using multiple indices can provide greater insight into the interactions in a system.},
  language  = {en}
}
@article{RemmeleXianAlbrechtetal.2014,
  author    = {Remmele, Christian W. and Xian, Yibo and Albrecht, Marco and Faulstich, Michaela and Fraunholz, Martin and Heinrichs, Elisabeth and Dittrich, Marcus T. and M{\"u}ller, Tobias and Reinhardt, Richard and Rudel, Thomas},
  title     = {Transcriptional landscape and essential genes of Neisseria gonorrhoeae},
  doi       = {10.1093/nar/gku762},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-113676},
  year      = {2014},
  abstract  = {The WHO has recently classified Neisseria gonorrhoeae as a super-bacterium due to the rapid spread of antibiotic resistant derivatives and an overall dramatic increase in infection incidences. Genome sequencing has identified potential genes, however, little is known about the transcriptional organization and the presence of non-coding RNAs in gonococci. We performed RNA sequencing to define the transcriptome and the transcriptional start sites of all gonococcal genes and operons. Numerous new transcripts including 253 potentially non-coding RNAs transcribed from intergenic regions or antisense to coding genes were identified. Strikingly, strong antisense transcription was detected for the phase-variable opa genes coding for a family of adhesins and invasins in pathogenic Neisseria, that may have regulatory functions. Based on the defined transcriptional start sites, promoter motifs were identified. We further generated and sequenced a high density Tn5 transposon library to predict a core of 827 gonococcal essential genes, 133 of which have no known function. Our combined RNA-Seq and Tn-Seq approach establishes a detailed map of gonococcal genes and defines the first core set of essential gonococcal genes.},
  language  = {en}
}
@article{SchererFallerFriedrichetal.2015,
  author    = {Scherer, Reinhold and Faller, Josef and Friedrich, Elisabeth V. C. and Opisso, Eloy and Costa, Ursula and K{\"u}bler, Andrea and M{\"u}ller-Putz, Gernot R.},
  title     = {Individually Adapted Imagery Improves Brain-Computer Interface Performance in End-Users with Disability},
  series = {PLoS ONE},
  volume    = {10},
  journal   = {PLoS ONE},
  number    = {5},
  doi       = {10.1371/journal.pone.0123727},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-143021},
  pages     = {e0123727},
  year      = {2015},
  abstract  = {Brain-computer interfaces (BCIs) translate oscillatory electroencephalogram (EEG) patterns into action. Different mental activities modulate spontaneous EEG rhythms in various ways. Non-stationarity and inherent variability of EEG signals, however, make reliable recognition of modulated EEG patterns challenging. Able-bodied individuals who use a BCI for the first time achieve - on average - binary classification performance of about 75\%. Performance in users with central nervous system (CNS) tissue damage is typically lower. User training generally enhances reliability of EEG pattern generation and thus also robustness of pattern recognition. In this study, we investigated the impact of mental tasks on binary classification performance in BCI users with central nervous system (CNS) tissue damage such as persons with stroke or spinal cord injury (SCI). Motor imagery (MI), that is the kinesthetic imagination of movement (e.g. squeezing a rubber ball with the right hand), is the "gold standard" and mainly used to modulate EEG patterns. Based on our recent results in able-bodied users, we hypothesized that pair- wise combination of "brain-teaser" (e.g. mental subtraction and mental word association) and "dynamic imagery" (e. g. hand and feet MI) tasks significantly increases classification performance of induced EEG patterns in the selected end-user group. Within- day (How stable is the classification within a day?) and between-day (How well does a model trained on day one perform on unseen data of day two?) analysis of variability of mental task pair classification in nine individuals confirmed the hypothesis. We found that the use of the classical MI task pair hand vs. feed leads to significantly lower classification accuracy - in average up to 15\% less - in most users with stroke or SCI. User-specific selection of task pairs was again essential to enhance performance. We expect that the gained evidence will significantly contribute to make imagery-based BCI technology become accessible to a larger population of users including individuals with special needs due to CNS damage.},
  language  = {en}
}
@article{SausseleHehlmannFabariusetal.2018,
  author    = {Saussele, Susanne and Hehlmann, Ruediger and Fabarius, Alice and Jeromin, Sabine and Proetel, Ulrike and Rinaldetti, Sebastien and Kohlbrenner, Katharina and Einsele, Hermann and Falge, Christine and Kanz, Lothar and Neubauer, Andreas and Kneba, Michael and Stegelmann, Frank and Pfreundschuh, Michael and Waller, Cornelius F. and Oppliger Leibundgut, Elisabeth and Heim, Dominik and Krause, Stefan W. and Hofmann, Wolf-Karsten and Hasford, Joerg and Pfirrmann, Markus and M{\"u}ller, Martin C. and Hochhaus, Andreas and Lauseker, Michael},
  title     = {Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV},
  series = {Leukemia},
  volume    = {32},
  journal   = {Leukemia},
  number    = {5},
  doi       = {10.1038/s41375-018-0055-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-227528},
  pages     = {1222-1228},
  year      = {2018},
  abstract  = {Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecular remission status Hazard ratios (HR) were estimated for patients registered to CML study IV who were divided in a learning and a validation sample. The minimum HR for MMR was found at 2.5 years with 0.28 (compared to patients without remission). In the validation sample, a significant advantage for progression-free survival (PFS) for patients in MMR could be detected (p-value 0.007). The optimal time to predict PFS in patients with MMR could be validated in an independent sample at 2.5 years. With our model we provide a suggestion when to define lack of MMR as therapy failure and thus treatment change should be considered. The optimal response time for 1\% BCR-ABL at about 12-15 months was confirmed and for deep molecular remission no specific time point was detected. Nevertheless, it was demonstrated that the earlier the MMR is achieved the higher is the chance to attain deep molecular response later.},
  language  = {en}
}
@article{RinaldettiPfirrmannManzetal.2018,
  author    = {Rinaldetti, S{\´e}bastien and Pfirrmann, Markus and Manz, Kirsi and Guilhot, Joelle and Dietz, Christian and Panagiotidis, Panayiotidis and Spiess, Birgit and Seifarth, Wolfgang and Fabarius, Alice and M{\"u}ller, Martin and Pagoni, Maria and Dimou, Maria and Dengler, Jolanta and Waller, Cornelius F. and Br{\"u}mmendorf, Tim H. and Herbst, Regina and Burchert, Andreas and Janßen, Carsten and Goebeler, Maria Elisabeth and Jost, Philipp J. and Hanzel, Stefan and Schafhausen, Philippe and Prange-Krex, Gabriele and Illmer, Thomas and Janzen, Viktor and Klausmann, Martine and Eckert, Robert and B{\"u}schel, Gerd and Kiani, Alexander and Hofmann, Wolf-Karsten and Mahon, Fran{\c{c}}ois-Xavier and Saussele, Susanne},
  title     = {Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial},
  series = {Clinical Lymphoma, Myeloma \& Leukemia},
  volume    = {18},
  journal   = {Clinical Lymphoma, Myeloma \& Leukemia},
  number    = {4},
  doi       = {10.1016/j.clml.2018.02.004},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226281},
  pages     = {266-271},
  year      = {2018},
  abstract  = {Within the EURO-SKI trial, 132 chronic phase CML patients discontinued imatinib treatment. RNA was isolated from peripheral blood in order to analyze the expression of MDR1, ABCG2 and OCT1. ABCG2 was predictive for treatment-free remission in Cox regression analysis. High transcript levels of the ABCG2 efflux transporter (>4.5 parts per thousand) were associated with a twofold higher risk of relapse. Introduction: Tyrosine kinase inhibitors (TKIs) can safely be discontinued in chronic myeloid leukemia (CML) patients with sustained deep molecular response. ABCG2 (breast cancer resistance protein), OCT1 (organic cation transporter 1), and ABCB1 (multidrug resistance protein 1) gene products are known to play a crucial role in acquired pharmacogenetic TKI resistance. Their influence on treatment-free remission (TFR) has not yet been investigated. Materials and Methods: RNA was isolated on the last day of TKI intake from peripheral blood leukocytes of 132 chronic phase CML patients who discontinued TKI treatment within the European Stop Tyrosine Kinase Inhibitor Study trial. Plasmid standards were designed including subgenic inserts of OCT1, ABCG2, and ABCB1 together with GUSB as reference gene. For expression analyses, quantitative real-time polymerase chain reaction was used. Multiple Cox regression analysis was performed. In addition, gene expression cutoffs for patient risk stratification were investigated. Results: The TFR rate of 132 patients, 12 months after TKI discontinuation, was 54\% (95\% confidence interval [CI], 46\%-62\%). ABCG2 expression (parts per thousand) was retained as the only significant variable (P=.02; hazard ratio, 1.04; 95\% CI, 1.01-1.07) in multiple Cox regression analysis. Only for the ABCG2 efflux transporter, a significant cutoff was found (P=.04). Patients with an ABCG2/GUSB transcript level >4.5 parts per thousand (n=93) showed a 12-month TFR rate of 47\% (95\% CI, 37\%-57\%), whereas patients with low ABCG2 expression (<= 4.5 parts per thousand; n=39) had a 12-month TFR rate of 72\% (95\% CI, 55\%-82\%). Conclusion: In this study, we investigated the effect of pharmacogenetics in the context of a CML treatment discontinuation trial. The transcript levels of the efflux transporter ABCG2 predicted TFR after TKI discontinuation. (C) 2018 The Authors. Published by Elsevier Inc.},
  language  = {en}
}